Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, ...
Interested parties may access the conference call on May 13, 2025, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the ...
Lineage Cell Therapeutics (AMEX:LCTX) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Lineage ...
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and ...
As we conclude a successful 2025, I want to extend my appreciation for your continued support of Lineage Cell Therapeutics and our mission to pioneer the emerging field of allogeneic cell therapy. I ...
New python toolkit automates single-cell lineage tracing, accelerates tumor drug resistance analysis
Researchers at Tsinghua University have released a novel Python toolkit, scLT-kit, which automates the processing and analysis of single-cell lineage tracing data, delivering clear insights into how ...
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results